HERON THERAPEUTICS, INC. /DE/ HRTX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-21.08
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $154.9M | -$20.2M | $113.6M | -$27.9M | $14.3M |
| 2024 | $144.3M | -$13.6M | $105.6M | -$24.2M | -$33.7M |
| 2023 | $127.0M | -$110.6M | $61.9M | -$60.3M | -$34.0M |
| 2022 | $107.7M | -$182.0M | $52.8M | -$148.7M | $13.6M |
| 2021 | $86.3M | -$220.7M | — | -$206.4M | $77.6M |
| 2020 | $88.6M | -$227.3M | — | -$191.6M | $236.5M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Duarte Ira | EVP, Chief Financial Officer | 2026-06-16 | Option exercise | 12,500 | — |
| Duarte Ira | EVP, Chief Financial Officer | 2026-06-16 | Tax withheld | 3,555 | $0.38 |
| Forbes William P | EVP, Chief Development Officer | 2026-06-06 | Option exercise | 12,500 | — |
| Hensley Mark Earl | Chief Operating Officer | 2026-05-06 | Option exercise | 125,000 | — |
| Hensley Mark Earl | Chief Operating Officer | 2026-04-30 | Option exercise | 11,770 | — |
| Forbes William P | EVP, Chief Development Officer | 2026-04-30 | Option exercise | 11,694 | — |
| Forbes William P | EVP, Chief Development Officer | 2026-04-30 | Option exercise | 11,770 | — |
| Duarte Ira | EVP, Chief Financial Officer | 2026-04-30 | Option exercise | 11,694 | — |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -21.08 (distress)
- Working capital / assets 0.555
- Retained earnings / assets -7.581
- EBIT / assets -0.01
- Equity / liabilities 0.059
Source: SEC EDGAR filings · CIK 0000818033 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.